Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.3%

Neg 0% Neu 87.3% Pos 0%

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.

Comments

No comments yet. Be the first!